Effects of a Comprehensive, Intensive Lifestyle Intervention Combined with Metformin Extended Release in Obese Adolescents

Overview

Journal Int Sch Res Notices

Specialty Biology

Date 2016 Jul 20

PMID 27433488

Citations 6

Authors

Cheril L Clarson

Hilary K Brown

Stefanie De Jesus

Michelle Jackman

Farid H Mahmud

Harry Prapavessis

Tracy Robinson

J Kevin Shoemaker

Margaret Watson

A Justine Dowd

David J Hill

Affiliations

Soon will be listed here.

Abstract

Objective. To assess a comprehensive, intensive lifestyle intervention in combination with metformin extended release (MXR) or placebo on body mass index (BMI) and risk factors for type 2 diabetes and cardiovascular disease in obese adolescents. Study Design. Sixty-nineobese adolescents (mean BMI 32.5) received a comprehensive lifestyle intervention with structured dietary, physical activity, and behavioral components for 24 months. Subjects were randomized to 1 of 4 groups: MXR (33) 2,000 mg daily or placebo, with either moderate or vigorous intensity exercise for the first 3 months. Subsequently the exercise intervention was the same for all 4 groups. Results. Anthropometry measurements did not differ with initial exercise intensity at any time. At 3 months % body fat decreased in all 4 groups (P < 0.006). BMI and % body fat decreased in the MXR groups, but not the placebo groups, at 6 (-0.88, -3.16) and 12 months (-0.56, -2.34) (P < 0.05). Insulin resistance, fasting blood glucose, and leptin improved in all groups at 6 and 12 months. A high subject attrition rate (58%) occurred by 24 months. Conclusion. A comprehensive, intensive lifestyle intervention combined with MXR led to a decline in BMI and % body fat at 1 year independent of initial exercise intensity. This trial is registered with ClinicalTrials.gov NCT00934570 .

Citing Articles

Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep-wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood....

Wilson C, Carpenter J, Nichles A, Zmicerevska N, Song Y, McHugh C BMJ Open. 2023; 13(2):e064682.

PMID: 36810174 PMC: 9945047. DOI: 10.1136/bmjopen-2022-064682.

Disparity Between United States Adolescent Class II and III Obesity Trends and Bariatric Surgery Utilization, 2015-2018.

Messiah S, Xie L, Atem F, Mathew M, Qureshi F, Schneider B Ann Surg. 2020; 276(2):324-333.

PMID: 32941272 PMC: 9825050. DOI: 10.1097/SLA.0000000000004493.

Effects of metformin in obesity treatment in different populations: a meta-analysis.

Pu R, Shi D, Gan T, Ren X, Ba Y, Huo Y Ther Adv Endocrinol Metab. 2020; 11:2042018820926000.

PMID: 32499908 PMC: 7243386. DOI: 10.1177/2042018820926000.

Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study.

Bassols J, Martinez-Calcerrada J, Osiniri I, Diaz-Roldan F, Xargay-Torrent S, Mas-Pares B PLoS One. 2019; 14(12):e0226303.

PMID: 31821361 PMC: 6903728. DOI: 10.1371/journal.pone.0226303.

Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.

Lentferink Y, Knibbe C, van der Vorst M Drugs. 2018; 78(18):1887-1901.

PMID: 30511324 DOI: 10.1007/s40265-018-1025-0.

References

Kolotourou M, Radley D, Chadwick P, Smith L, Orfanos S, Kapetanakis V . Is BMI alone a sufficient outcome to evaluate interventions for child obesity?. Child Obes. 2013; 9(4):350-6. PMC: 3728723. DOI: 10.1089/chi.2013.0019. View

Amed S, Dean H, Panagiotopoulos C, Sellers E, Hadjiyannakis S, Laubscher T . Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care. 2010; 33(4):786-91. PMC: 2845028. DOI: 10.2337/dc09-1013. View

Ali S, Fonseca V . Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012; 13(12):1797-805. DOI: 10.1517/14656566.2012.705829. View

Racil G, Ben Ounis O, Hammouda O, Kallel A, Zouhal H, Chamari K . Effects of high vs. moderate exercise intensity during interval training on lipids and adiponectin levels in obese young females. Eur J Appl Physiol. 2013; 113(10):2531-40. DOI: 10.1007/s00421-013-2689-5. View

Sandhu N, Witmans M, Lemay J, Crawford S, Jadavji N, Pacaud D . Prevalence of overweight and obesity in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2008; 21(7):631-40. DOI: 10.1515/JPEM.2008.21.7.631. View

Justine Wilson A, Jung M, Cramp A, Simatovic J, Prapavessis H, Clarson C . Effects of a group-based exercise and self-regulatory intervention on obese adolescents' physical activity, social cognitions, body composition and strength: a randomized feasibility study. J Health Psychol. 2012; 17(8):1223-37. DOI: 10.1177/1359105311434050. View

Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury V, OMalley C, Stolk R . Interventions for treating obesity in children. Cochrane Database Syst Rev. 2009; (1):CD001872. DOI: 10.1002/14651858.CD001872.pub2. View

Wiegand S, lAllemand D, Hubel H, Krude H, Burmann M, Martus P . Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010; 163(4):585-92. DOI: 10.1530/EJE-10-0570. View

Park M, Kinra S, Ward K, White B, Viner R . Metformin for obesity in children and adolescents: a systematic review. Diabetes Care. 2009; 32(9):1743-5. PMC: 2732169. DOI: 10.2337/dc09-0258. View

10.

Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Merinbaum D . Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012; 25(1-2):33-40. PMC: 4005723. DOI: 10.1515/jpem-2011-0450. View

11.

Roberts K, Shields M, de Groh M, Aziz A, Gilbert J . Overweight and obesity in children and adolescents: results from the 2009 to 2011 Canadian Health Measures Survey. Health Rep. 2012; 23(3):37-41. View

12.

Freemark M, Bursey D . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001; 107(4):E55. DOI: 10.1542/peds.107.4.e55. View

13.

Love-Osborne K, Sheeder J, Zeitler P . Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008; 152(6):817-22. PMC: 2585976. DOI: 10.1016/j.jpeds.2008.01.018. View

14.

Franks P, Hanson R, Knowler W, Moffett C, Enos G, Infante A . Childhood predictors of young-onset type 2 diabetes. Diabetes. 2007; 56(12):2964-72. PMC: 6419722. DOI: 10.2337/db06-1639. View

15.

McDonagh M, Selph S, Ozpinar A, Foley C . Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2013; 168(2):178-84. DOI: 10.1001/jamapediatrics.2013.4200. View

16.

Shields M . Overweight and obesity among children and youth. Health Rep. 2006; 17(3):27-42. View

17.

Ford A, Hunt L, Cooper A, Shield J . What reduction in BMI SDS is required in obese adolescents to improve body composition and cardiometabolic health?. Arch Dis Child. 2009; 95(4):256-61. DOI: 10.1136/adc.2009.165340. View

18.

Justine Wilson A, Prapavessis H, Jung M, Cramp A, Vascotto J, Lenhardt L . Lifestyle modification and metformin as long-term treatment options for obese adolescents: study protocol. BMC Public Health. 2009; 9:434. PMC: 2797799. DOI: 10.1186/1471-2458-9-434. View

19.

Wilson D, Abrams S, Aye T, Lee P, Lenders C, Lustig R . Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010; 164(2):116-23. PMC: 3499098. DOI: 10.1001/archpediatrics.2009.264. View

20.

Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F . Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2012; 98(1):322-9. DOI: 10.1210/jc.2012-2710. View